Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

Kyne L, Warny M, Qamar A, Kelly CP.

Lancet. 2001 Jan 20;357(9251):189-93.

PMID:
11213096
2.

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Kyne L, Warny M, Qamar A, Kelly CP.

N Engl J Med. 2000 Feb 10;342(6):390-7.

3.

Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.

Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Kleanthous H.

J Med Microbiol. 2013 Sep;62(Pt 9):1394-404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21.

PMID:
23518659
4.

Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease.

Katchar K, Taylor CP, Tummala S, Chen X, Sheikh J, Kelly CP.

Clin Gastroenterol Hepatol. 2007 Jun;5(6):707-13.

PMID:
17544998
5.

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).

Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D.

Vaccine. 2010 Jan 22;28(4):965-9. doi: 10.1016/j.vaccine.2009.10.144. Epub 2009 Nov 24.

PMID:
19941990
6.

Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.

Warny M, Vaerman JP, Avesani V, Delmée M.

Infect Immun. 1994 Feb;62(2):384-9.

7.

Human antibody response to surface layer proteins in Clostridium difficile infection.

Drudy D, Calabi E, Kyne L, Sougioultzis S, Kelly E, Fairweather N, Kelly CP.

FEMS Immunol Med Microbiol. 2004 Jul 1;41(3):237-42.

9.

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea.

Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP.

Gastroenterology. 2005 Mar;128(3):764-70.

PMID:
15765411
10.

Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.

Johnson S, Gerding DN, Janoff EN.

J Infect Dis. 1992 Dec;166(6):1287-94.

PMID:
1431247
11.

Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.

Monaghan TM, Robins A, Knox A, Sewell HF, Mahida YR.

PLoS One. 2013 Sep 10;8(9):e74452. doi: 10.1371/journal.pone.0074452. eCollection 2013.

12.

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.

Salcedo J, Keates S, Pothoulakis C, Warny M, Castagliuolo I, LaMont JT, Kelly CP.

Gut. 1997 Sep;41(3):366-70.

14.

The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.

Yang XQ, Zhao YG, Chen XQ, Jiang B, Sun DY.

BMC Gastroenterol. 2013 Jul 17;13:117. doi: 10.1186/1471-230X-13-117.

15.

Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls.

Sánchez-Hurtado K, Corretge M, Mutlu E, McIlhagger R, Starr JM, Poxton IR.

J Med Microbiol. 2008 Jun;57(Pt 6):717-24. doi: 10.1099/jmm.0.47713-0.

PMID:
18480328
16.

Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.

Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD Jr.

Infect Immun. 2006 Nov;74(11):6339-47. Epub 2006 Sep 11.

17.

IgG antibody response to toxins A and B in patients with Clostridium difficile infection.

Wullt M, Norén T, Ljungh A, Åkerlund T.

Clin Vaccine Immunol. 2012 Sep;19(9):1552-4. doi: 10.1128/CVI.00210-12. Epub 2012 Jul 11.

18.

Role of antibody response in outcome of antibiotic-associated diarrhoea.

Wilcox M, Minton J.

Lancet. 2001 Jan 20;357(9251):158-9. No abstract available.

PMID:
11213086
19.

Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.

Roberts A, McGlashan J, Al-Abdulla I, Ling R, Denton H, Green S, Coxon R, Landon J, Shone C.

Infect Immun. 2012 Feb;80(2):875-82. doi: 10.1128/IAI.05684-11. Epub 2011 Dec 5.

20.

Supplemental Content

Support Center